A simple blood test might one day tell doctors which lymphoma patients are likely to respond to a powerful immunotherapy, sparing others from an invasive and costly treatment that may not work for them, according to new research from Cornell University and Dana-Farber Cancer Institute.
The study, published Nov. 18 in the journal Cell Reports Medicine, analyzed plasma samples from 91 patients with large B-cell lymphoma who received anti-CD19 CAR T-cell therapy at Dana-Farber. The researchers found that fragments of genetic material called cell-free RNA, shed by cells into the bloodstream, carry a signature of the tumor's local environment — and that signature tracked closely with whether patients stayed in remission a year after treatment.
Patients whose blood showed a high score on that signature before treatment had an 80% lower risk of their cancer progressing compared with those who scored low, according to the study.
CAR T-cell therapy, which engineers a patient's own immune cells to hunt down cancer, has transformed care for people with large B-cell lymphoma. But nearly half of patients either do not respond initially or relapse within a year, and doctors have had few reliable ways to predict who will benefit.
"CAR T-cell therapy is one of the major breakthroughs of the past couple of decades, but not every patient responds," said Iwijn De Vlaminck, professor in the Meinig School of Biomedical Engineering at Cornell and the study's lead researcher.
Glory Feyisayo Agun, a doctoral student in De Vlaminck's lab and one of the study's first authors, said the treatment's complexity makes outcomes hard to anticipate. "CAR T-cell therapy has a strong overall response rate that drops over time, but the factors driving differences in patient response are not fully understood," she said.
Reading the neighborhood
Recent research has pointed to the tumor microenvironment — the mix of immune cells, structural cells and blood vessels surrounding a tumor — as a key factor in treatment success. A 2025 study in the journal Cancer Cell classified lymphomas into three types based on biopsy samples. Tumors with a "lymph node-like" environment responded better to CAR T therapy, while two other types — one dominated by exhausted T cells and one by follicular macrophages and accessory cells — were linked to treatment failure.
De Vlaminck's team wondered whether a blood draw could reveal the same information without the need for an invasive tissue biopsy. "RNA that is circulating in blood plasma might provide the signal, which gives you a window not just to the immune system but also potentially to tissues," he said. "The advantage is that you can sample it noninvasively."
The researchers analyzed plasma collected before treatment from patients receiving a specific CAR T product across three separate groups. The median patient age was 65. The lymph node-like signature showed up clearly in the plasma RNA of patients who responded, mirroring what the earlier biopsy study had found in tumor tissue. Patients with above-median scores had significantly longer survival in all three groups.
The signal was absent from immune cells circulating in the blood, which the team examined in matched samples, suggesting the plasma RNA reflects activity in the tissue itself rather than a change in the blood's cellular makeup.
"We don't see that with circulating cells," Agun said. "This is one of the first times we're seeing this with plasma being a proxy for the tumor environment."
"Being able to access it from the blood — and not tissue — is a major advance, in our opinion, because it's minimally invasive," De Vlaminck said.
Not just a measure of tumor burden
One obvious concern is that the signature simply reflects how much cancer a patient has. The researchers checked against a standard proxy for tumor burden, lactate dehydrogenase, and found no significant correlation before chemotherapy preparation. In statistical models, the score also predicted response better than clinical factors. The team ran several other tests suggesting the signature is specific to CAR T response.
Next steps
The authors caution that the model needs validation in larger, multi-institution studies. The findings have not yet been shown to change patient outcomes.
"The study was focused on a specific patient group," Agun said. "The next step would be to expand that to other patients who are receiving CAR T therapy. Next would be validating across a cohort and seeing if this is reproducible across different contexts."
If the findings hold, the researchers envision two potential uses. Doctors could identify patients with unfavorable tumor environments before infusion and offer them additional therapies aimed at reshaping that environment, such as targeted radiation or drugs aimed at macrophages. A blood test could also confirm that such an intervention had worked before CAR T cells are given.
"This approach has potential beyond lymphoma," said co-first author Conor Loy, Ph.D. '24 and co-founder of Romix Biosciences, a biotechnology startup combining cell-free RNA and AI to advance precision medicine. "This technology could help guide treatment decisions, matching patients to treatments that are right for them, and helping doctors to choose treatment to pair with immunotherapies."